Orum Therapeutics is a private, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of novel tumor-selective, targeted protein degraders (TPDs). Their proprietary Oromab™ platform combines the cell-specific delivery of antibodies with the potent cell-killing mechanism of protein GSPT1 degradation. This approach aims to create highly effective therapies with improved safety profiles for hard-to-treat cancers. Orum's pipeline includes candidates for solid tumors and hematologic malignancies, with ongoing clinical trials.
The Cambridge headquarters serves as the central hub for corporate strategy, business development, clinical operations leadership, investor relations, and global program management.
Located within the Cambridge Innovation Center (CIC), providing access to state-of-the-art facilities, flexible workspaces, and a vibrant community of innovators and entrepreneurs.
The work culture is characterized by a strong emphasis on scientific rigor, innovation, and collaboration. As a clinical-stage biotech, the environment is dynamic, fast-paced, and mission-driven, focused on advancing treatments for patients.
Its location in Kendall Square places Orum at the epicenter of the biotech world, offering unparalleled access to leading academic institutions, research talent, potential partners, and investors.
Orum Therapeutics operates with a global mindset, leveraging its dual presence in the USA and South Korea. The Cambridge, MA headquarters manages global clinical development, strategic partnerships, and business operations, while the Daejeon R&D center drives discovery and innovation. This structure allows Orum to access global talent, engage with international research communities, and conduct clinical trials across different regions to bring its cancer therapies to patients worldwide.
One Broadway, 14th Floor
Cambridge
MA
USA
Address: Bio-Innovation Complex, 60, Daehak-ro 4-gil, Yuseong-gu, Daejeon 34134, Republic of Korea
Leverages South Korea's advanced biotech infrastructure, skilled scientific talent pool, and supportive R&D environment to drive early-stage innovation and pipeline development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Orum Therapeutics' leadership includes:
Orum Therapeutics has been backed by several prominent investors over the years, including:
Orum Therapeutics has significantly strengthened its leadership team over the past year with key C-suite appointments to drive its clinical and operational growth.
Discover the tools Orum Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for Orum Therapeutics likely follow standard professional patterns. While not publicly confirmed, a frequent structure used by similar companies is [first_initial][last]@orumrx.com.
[first_initial][last]@orumrx.com
Format
jdoe@orumrx.com
Example
70%
Success rate
Orum Therapeutics • May 15, 2024
Orum Therapeutics announced it presented preclinical data from two programs, ORM-5029 and ORM-6151, at the 5th Annual GSPT1-Focused Targeted Protein Degradation (TPD) Summit. The data highlighted the potential of its GSPT1 degraders using the Oromab™ platform for treating HER2-expressing solid tumors and AML....more
Orum Therapeutics • January 4, 2024
Orum Therapeutics announced the dosing of the first patient in its Phase 1 clinical trial evaluating ORM-6151 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS)....more
Orum Therapeutics • July 11, 2023
Orum Therapeutics announced the appointment of Jacob S. Lee, M.D., M.B.A., as its Chief Medical Officer. Dr. Lee brings over 20 years of experience in oncology drug development to lead Orum's clinical strategy and operations....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Orum Therapeutics, are just a search away.